We randomly assigned 46 patients (mean age, 11.7 years; range, 4.5 to 32.8) with newly diagnosed insulin-dependent diabetes mellitus within two weeks of beginning insulin to receive either corticosteroids for 10 weeks plus daily azathioprine for one year or no immunosuppressive therapy. Half the 20 immunosuppressed patients completing the one-year trial had satisfactory metabolic outcomes (hemoglobin A1c less than 6.8 percent; stimulated peak C peptide greater than 0.5 nmol per liter; insulin dose less than 0.4 U per kilogram of body weight per day) as compared with only 15 percent of the controls. Three of 20 immunosuppressed patients, but no controls, were insulin independent at one year. Two of these continue to receive azathioprine without insulin after more than 27 months of follow-up. The response to immunosuppression correlated with older age, better initial metabolic status, and lymphopenia (less than 1800 lymphocytes per cubic millimeter) resulting from immunosuppression. The side effects of azathioprine included vomiting in one patient and mild hair loss in several others. Prednisone use resulted in a transient cushingoid appearance, weight gain, and hyperglycemia. The growth rate remained normal in all patients. We conclude that early immunosuppression with short-term use of corticosteroids plus daily azathioprine can improve metabolic control in some patients with insulin-dependent diabetes mellitus, but results from this unblinded study are preliminary and require further confirmation and long-term follow-up.
Source Information
Department of Pediatrics, University of Florida, Gainesville.
This article has been cited by other articles:
Haller, M. J., Wasserfall, C. H., McGrail, K. M., Cintron, M., Brusko, T. M., Wingard, J. R., Kelly, S. S., Shuster, J. J., Atkinson, M. A., Schatz, D. A.
(2009). Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes. Diabetes Care
32: 2041-2046
[Abstract][Full Text]
Rother, K. I., Brown, R. J., Morales, M. M., Wright, E., Duan, Z., Campbell, C., Hardin, D. S., Popovic, J., McEvoy, R. C., Harlan, D. M., Orlander, P. R., Brod, S. A.
(2009). Effect of Ingested Interferon-{alpha} on {beta}-Cell Function in Children With New-Onset Type 1 Diabetes. Diabetes Care
32: 1250-1255
[Abstract][Full Text]
Concannon, P., Rich, S. S., Nepom, G. T.
(2009). Genetics of Type 1A Diabetes. NEJM
360: 1646-1654
[Full Text]
Couri, C. E. B., Oliveira, M. C. B., Stracieri, A. B. P. L., Moraes, D. A., Pieroni, F., Barros, G. M. N., Madeira, M. I. A., Malmegrim, K. C. R., Foss-Freitas, M. C., Simoes, B. P., Martinez, E. Z., Foss, M. C., Burt, R. K., Voltarelli, J. C.
(2009). C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA
301: 1573-1579
[Abstract][Full Text]
Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simoes, B. P., Foss, M. C., Squiers, E., Burt, R. K.
(2007). Ethics of Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus--Reply. JAMA
298: 285-286
[Full Text]
Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simoes, B. P., Foss, M. C., Squiers, E., Burt, R. K.
(2007). Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA
297: 1568-1576
[Abstract][Full Text]
Haller, M. J., Schatz, D. A., Schwartz, I. D., Keymeulen, B., Pipeleers, D., Chatenoud, L.
(2005). CD3-antibody therapy in new-onset type 1 diabetes mellitus.. NEJM
353: 2086-2087
[Full Text]
Narendran, P., Estella, E., Fourlanos, S.
(2005). Immunology of type 1 diabetes. QJM
98: 547-556
[Full Text]
Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., Bluestone, J. A.
(2005). A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes. Diabetes
54: 1763-1769
[Abstract][Full Text]
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., Steffes, M. W.
(2004). C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001. Diabetes
53: 250-264
[Abstract][Full Text]
Bloomgarden, Z. T.
(2003). Diabetes Issues in Women and Children: Polycystic ovary syndrome. Diabetes Care
26: 2457-2463
[Full Text]
Greenbaum, C. J., Harrison, L. C.
(2003). Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes. Diabetes
52: 1059-1065
[Full Text]
Brod, S. A.
(2002). Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity. Exp Biol Med
227: 981-988
[Abstract][Full Text]
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., Bluestone, J. A.
(2002). Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. NEJM
346: 1692-1698
[Abstract][Full Text]
Winter, W.E.
(1996). Type I Insulin-Dependent Diabetes Mellitus: a Model for Autoimmune Polygenic Disorders. ADR
10: 81-87
[Abstract]
Atkinson, M. A., Maclaren, N. K.
(1994). The Pathogenesis of Insulin-Dependent Diabetes Mellitus. NEJM
331: 1428-1436
[Full Text]
Winter, W. E., Chihara, T., Schatz, D.
(1993). The Genetics of Autoimmune Diabetes: Approaching a Solution to the Problem. Arch Pediatr Adolesc Med
147: 1282-1290
[Abstract]
(1988). MORE EVIDENCE FOR SHORT-TERM BENEFIT OF IMMUNOSUPPRESSIVE THERAPY IN DIABETES. JWatch General
1988: 6-6
[Full Text]
Previous
